FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.

"Declarations Ethics approval and consent to participateAll animal experiments in this study were evaluated and approved by the Institutional Animal Ethics Committee of East China Normal University. Human lung adenocarcinoma tissues and adjacent normal tissues were collected and handled according to the ethical and safety procedures approved by the Clinical Ethics Committee of the Huzhou Central Hospital, Affiliated Hospital of Zhejiang University and the lung cancer tissue array (HLugA180Su08) was purchased from Shanghai Outdo Biotech. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by the National Key R&D Program of China (2023YFC3402000 to B.D.); National Natural Science Foundation of China (32270960 to B.D., 82173099 to J.Q., 81830083 to M.L.); Program of Shanghai Academic/Technology Research Leader (23XD1430600 to B.D.); Science and Technology Commission of Shanghai Municipality (23141901800 to B.D., 23141903300 to J.Q.)."